Filspari was Travere Therapeutics’s largest product and service line in fiscal 2025, bringing in $322.01M of $483.16M (67%).
| Product and Service | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2023 | FY 2024 | FY 2025 | FY 2025 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Filspari | $29.21M | $132.22M | — | — | $322.01M | |||||||
| Thiola License | — | — | — | — | — | |||||||
| Tiopronin Products | $98.33M | $94.49M | — | — | $88.46M | |||||||
| Bile Acid Products | — | — | — | — | — | |||||||
| Market Access Milestone | — | — | — | $40.00M | $40.00M | |||||||
| Regulatory Milestone | — | — | $17.50M | — | $17.50M | |||||||
| License & Collaboration Revenue | $17.70M | $6.47M | — | — | $9.30M | |||||||
| Royalty | — | $600.00K | — | — | $5.90M | |||||||
| Total | $145.24M | $233.78M | $17.50M | $40.00M | $483.16M |
Travere Therapeutics brought in $483.16M from its six product and service lines in fiscal 2025, the year ended December 31, 2025. Travere Therapeutics regrouped these lines after fiscal 2025, so the total does not compare directly with that year's $40.00M. Filspari was the largest at $322.01M (66.6%), ahead of Tiopronin Products at $88.46M (18.3%) and Market Access Milestone at $40.00M (8.3%). The other three lines brought in $32.70M combined.
Travere Therapeutics began breaking out Market Access Milestone in fiscal 2025, Regulatory Milestone in fiscal 2025 and Royalty in fiscal 2024.
Travere Therapeutics (TVTX) reports its revenue by product and service. In fiscal 2025, Filspari was its largest product and service line, bringing in $322.01M (66.6% of the total), followed by Tiopronin Products at $88.46M (18.3%).
Filspari was Travere Therapeutics' largest product and service line in fiscal 2025, bringing in $322.01M, or 66.6% of the $483.16M total across its six product and service lines.
Every figure comes from Travere Therapeutics' annual financial filings, as reported. Each line keeps the name Travere Therapeutics gives it, and years follow its fiscal calendar.
Travere Therapeutics' revenue by product and service goes back to fiscal 2015, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.